Two Very Different Ways to Attack a Tumor

Chemotherapy and immunotherapy are often mentioned in the same breath, but they work on completely different principles. Chemo is a direct poison to dividing cells: it circulates through the body and kills cells that are replicating quickly, which is why it hits tumors but also hair follicles, the lining of the mouth, and blood counts. Immunotherapy does not attack cancer directly. It removes the brakes on the immune system so that T cells can recognize and destroy cancer cells on their own.

That difference shows up in almost everything a patient notices: how the drugs are given, how long treatment lasts, what side effects appear, and how quickly results arrive. A patient in Ohio starting pembrolizumab for melanoma and a patient in Texas starting carboplatin for lung cancer are on schedules that look nothing alike, even though both sit in an infusion chair every few weeks.

One practical distinction matters early: chemo usually produces measurable shrinkage within a few cycles, while immunotherapy can take eight to twelve weeks or longer to show a response on a scan, and sometimes tumors appear to grow slightly before they shrink. Doctors call that pseudoprogression, and it is a common source of anxiety for families expecting instant results.

Side Effects: Immediate Damage vs. Immune Overdrive

Chemo side effects are predictable and tied to the dose. Nausea, hair loss, mouth sores, fatigue, and low white blood cell counts follow a fairly standard timeline, and oncology teams have well-worn protocols for each. Most chemo side effects resolve after treatment ends.

Immunotherapy side effects are different in kind. Because the immune system is being unleashed, the problems are inflammatory: rash, colitis with diarrhea, thyroid dysfunction, hepatitis, and in rare cases inflammation of the lungs or pituitary gland. These can appear months after the first infusion and, unlike chemo effects, may persist or flare after the drug is stopped. Patients on checkpoint inhibitors often carry a steroid taper plan and a wallet card listing their drug in case they land in an emergency room.

Why the Combination Is Sometimes Used

For some cancers, including certain lung and kidney tumors, oncologists combine chemo and immunotherapy. The chemo debulks the tumor and releases antigens, and the immunotherapy helps the immune system mop up what remains. The trade-off is a heavier side-effect profile, so eligibility depends on age, organ function, and performance status. When patients ask what is the difference between chemotherapy and immunotherapy in terms of tolerability, the honest answer is that the combination is harder than either alone.

Schedules, Cost, and Access in the United States

Chemo is typically given in cycles of two to four weeks with a defined end point, often three to six months. Immunotherapy is often given every three, four, or six weeks and can continue for up to two years, sometimes longer, even after the tumor is no longer visible. That duration changes the financial picture. An immunotherapy infusion can run $10,000 to $15,000 or more per dose before insurance, while generic chemo drugs such as cisplatin cost a fraction of that. Medicare Part B generally covers infusions administered in a hospital outpatient department or clinic, and most commercial plans cover checkpoint inhibitors for FDA-approved indications.

Prior authorization is the practical hurdle. Insurers frequently require biomarker testing first — PD-L1 expression, MSI status, or tumor mutational burden — before approving an immunotherapy drug. If a patient is weighing the difference between chemo and immunotherapy for a parent, the first useful question for the oncologist is which biomarkers have been tested and whether the tumor has an approved indication for a checkpoint inhibitor.

Questions Worth Asking Before Treatment Starts

The choice is rarely abstract. A retired teacher in Tucson with stage III colon cancer may be offered surgery followed by chemo, while a patient with advanced melanoma may go straight to immunotherapy plus targeted therapy. The right answer depends on cancer type, stage, biomarkers, and the patient’s other health conditions — autoimmune disease, for instance, raises the risk of immunotherapy complications and may push the decision toward chemo.

Ask three things: what is the goal of this treatment (cure, control, or symptom relief), what response rate does the regimen have for my exact cancer and biomarker profile, and what is the plan if the first scan shows no change. Get the answer in writing. It makes the follow-up visit far easier to navigate, and it keeps everyone honest about what the treatment is meant to accomplish.